Edwards Lifesciences Corporation

US$102.14As of Sun 8 Nov 2026, 12:00 UTC
NYSE:EWHealthcare
Country USA
PE (Fwd) •••
TSR 10Y CAGR 12.37%
Div yield —
ROE 9.33%
Medical Devices
Beta (5Y) 0.83
PE TTM 57.98
TSR TTM 23.88%
Mkt cap US$58.73B
ROIC 18.68%
SE Grade™
Value
Quality
Moat
Consensus
Reference
$99
(3.36%)
(27.79%)
Hold 11|9|3|2|6
4Q25
1Q26
2Q26
3Q26
Earnings per share$
1.24
1.35
1.51
1.64
12.53%
15.52%
28.89%
26.72%
Revenue$B
3.848
4.000
3.985
4.162
5.48%
11.94%
12.85%
13.14%
Peers (US$58.73B)
Cap (US$)
PE
61.96B
18.05x
29.62B
31.14x
Capital
TTM
5Y
10Y
Leveragex
5.563
0.666
0.580
EBIT/Intx
1.284
0.202
0.189
Own earn%
65.12
11.54
11.58
Sh yield%
19.84
6.43
5.25
Owners
Insiders/Inst%
4.05
67.09
Short interest%
2.79
SBC / revenue%
0.41
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
12
Op margin range%
19–26
$1 testx
0.0
Incr. ROIC%
14

Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally, including Edwards SAPIEN transcatheter aortic valves, PASCAL and EVOQUE mitral and tricuspid repair and replacement products, and INSPIRIS, KONECT RESILIA and MITRIS RESILIA surgical valves, sold through a direct sales force and independent distributors.